Department of Neurosurgery, Brain Research Institute, University of Niigata, Niigata, Japan.
Center for Integrated Brain Sciences, Brain Research Institute, University of Niigata, Niigata, Japan.
Acta Neuropathol Commun. 2014 Nov 7;2:158. doi: 10.1186/s40478-014-0158-y.
Previous magnetic resonance spectroscopy (MRS) and mass spectroscopy studies have shown accumulation of 2-hydroxyglutarate (2HG) in mutant isocitrate dehydrogenase (IDH) gliomas. IDH mutation is known to be a powerful positive prognostic marker in malignant gliomas. Hence, 2HG accumulation in gliomas was assumed to be a positive prognostic factor in gliomas, but this has not yet been proven. Here, we analyzed 52 patients harboring World Health Organization (WHO) grade II and III gliomas utilizing 3.0-tesla MRS.
Mutant IDH gliomas showed significantly higher accumulation of 2HG (median 5.077 vs. 0.000, p =0.0002, Mann-Whitney test). 2HG was detectable in all mutant IDH gliomas, whereas in 10 out of 27 (37.0%) wild-type IDH gliomas, 2HG was below the detectable range (2HG =0) (p =0.0003, chi-squared test). Screening for IDH mutation by 2HG analysis was highly sensitive (cutoff 2HG =1.489 mM, sensitivity 100.0%, specificity 72.2%). Gliomas with high 2HG accumulation had better overall survival than gliomas with low 2HG accumulation (p =0.0401, Kaplan-Meier analysis).
2HG accumulation detected by 3.0-tesla MRS not only correlates well with IDH status, but also positively correlates with survival in WHO grade II and III gliomas.
先前的磁共振波谱(MRS)和质谱研究表明,2-羟戊二酸(2HG)在突变型异柠檬酸脱氢酶(IDH)胶质瘤中积累。IDH 突变已知是恶性胶质瘤强有力的阳性预后标志物。因此,胶质瘤中 2HG 的积累被认为是胶质瘤的一个阳性预后因素,但这尚未得到证实。在这里,我们利用 3.0 特斯拉 MRS 分析了 52 例携带世界卫生组织(WHO)二级和三级胶质瘤的患者。
突变型 IDH 胶质瘤中 2HG 的积累明显更高(中位数 5.077 与 0.000,p =0.0002,Mann-Whitney 检验)。所有突变型 IDH 胶质瘤中均可检测到 2HG,而在 27 例野生型 IDH 胶质瘤中有 10 例(37.0%)低于检测范围(2HG =0)(p =0.0003,卡方检验)。通过 2HG 分析筛查 IDH 突变具有很高的敏感性(截断值 2HG =1.489 mM,敏感性 100.0%,特异性 72.2%)。2HG 积累较高的胶质瘤总生存时间优于 2HG 积累较低的胶质瘤(p =0.0401,Kaplan-Meier 分析)。
3.0 特斯拉 MRS 检测到的 2HG 积累不仅与 IDH 状态密切相关,而且与 WHO 二级和三级胶质瘤的生存呈正相关。